From Startup Eidos Therapeutics
SAN FRANCISCO, Oct. 29, 2018 (GLOBE NEWSWIRE) — Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX) today announced that management will host a conference call and webcast to discuss the results of its Phase 2 clinical trial of AG10 in patients with transthyretin amyloidosis cardiomyopathy and symptomatic heart failure following the late-breaking Featured Science oral presentation at the American Heart Association’s Annual Scientific Sessions. The call will occur on Monday, November 12, at 8:00 a.m. ET.
The conference call will include a presentation followed by a Q&A session and will be accessible through an audio webcast at ir.eidostx.com. An archived replay of the webcast will be available on the company’s website for 90 days following the live presentation.
The conference call can be accessed in a listen-only mode as follows: +1-844-293-0174 (U.S. toll free) or +1-916-582-3546 (international), conference ID 8594856.
AG10 is an investigational, orally administered small molecule designed to potently stabilize tetrameric transthyretin, or TTR, thereby halting at its outset the series of molecular events that give rise to amyloidosis, or ATTR. AG10 is currently being examined in a Phase 2 clinical trial in patients with ATTR cardiomyopathy and symptomatic heart failure. Results from this trial will be presented on November 10, 2018 at the American Heart Association’s Annual Scientific Sessions.
AG10 was designed to mimic a naturally-occurring variant of the TTR gene (T119M) that is considered a “rescue mutation” because it has been shown to prevent ATTR in individuals also carrying a pathogenic, or disease-causing, mutation in the other copy of their TTR gene. To our knowledge, AG10 is the only TTR stabilizer in development that has been observed to mimic the “super-stabilizing” properties of this rescue mutation.
About Eidos Therapeutics
Eidos Therapeutics is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR). For more information, please visit www.eidostx.com.
Media Contact:Carolyn HawleyCanale Communications619-849-5382Carolyn@canalecomm.com
Investor Contact:Alex GrayBurns McClellan212firstname.lastname@example.org
Source: Eidos Therapeutics, Inc.
Please visit their site for more information: Eidos Therapeutics
All,Biotechnology,Healthcare News,Startup News